1
Levy Odile Esther, Hanley Michael R, Jodka Carolyn M, Lewis Diana Y, Soares Christopher J, Ghosh Soumitra S, D Souza Lawrence J, Parkes David G, Mack Christine M: Hybrid polypeptides with selectable properties. Amylin Pharmaceuticals, Levy Odile Esther, Hanley Michael R, Jodka Carolyn M, Lewis Diana Y, Soares Christopher J, Ghosh Soumitra S, D Souza Lawrence J, Parkes David G, Mack Christine M, MARSH David R, August 25, 2005: WO/2005/077072 (19 worldwide citation)

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-rel ...


2

3

4
Ghosh Soumitra Shankar, Lewis Diana Y, Janssen Samuel, Srivastava Ved, Liu Que, Jodka Carolyn M, Soares Christopher J, Lin Qing: Composition and methods for treatment of congestive heart failure. Amylin Pharmaceuticals, Ghosh Soumitra Shankar, Lewis Diana Y, Janssen Samuel, Srivastava Ved, Liu Que, Jodka Carolyn M, Soares Christopher J, Lin Qing, BUTLER James E, December 6, 2007: WO/2007/139941 (6 worldwide citation)

Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in the m ...


5
Levy Odile Esther, Hanley Michael R, Jodka Carolyn M, Lewis Diana Y, Soares Christopher J, Ghosh Soumitra S, D Souza Lawrence J, Parkes David G, Mack Christine M: Hybrid polypeptides with selectable properties. Amylin Pharmaceuticals, November 8, 2006: EP1718665-A2 (3 worldwide citation)

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-rel ...


6
SOARES CHRISTOPHER J, HANLEY MICHAEL R, LEWIS DIANA Y, PARKES DAVID G, JODKA CAROLYN M, PRICKETT KATHRYN S, GHOSH SOUMITRA, MACK CHRISTINE M, LIN QING: [fr] Peptides de la famille des amylines et leurs procédés de fabrication et dutilisation, [de] Peptide der amylin Familie, Verfahren zu deren Herstellung und Verwendung, [en] Amylin family peptides and methods for making and using them. AMYLIN PHARMACEUTICALS, September 29, 2010: EP2233497-A2 (2 worldwide citation)

[en] The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In add ...


7
LEVY ODILE ESTHER, HANLEY MICHAEL R, JODKA CAROLYN M, LEWIS DIANA Y, SOARES CHRISTOPHER J, GHOSH SOUMITRA S, PARKES DAVID G, MACK CHRISTINE M, D SOUZA LAWRENCE J: [fr] Polypeptides hybrides présentant des propriétés pouvant être choisies, [de] Hybridpolypeptide mit auswahlbaren Eigenschaften, [en] Hybrid polypeptides with selectable properties. AMYLIN PHARMACEUTICALS, February 29, 2012: EP2422806-A2

[en] The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabete ...


8
LEVY ODILE ESTHER, HANLEY MICHAEL R, JODKA CAROLYN M, LEWIS DIANA Y, SOARES CHRISTOPHER J, GHOSH SOUMITRA S, PARKES DAVID G, MACK CHRISTINE M, D SOUZA LAWRENCE J: [fr] Polypeptides hybrides présentant des propriétés pouvant être choisies, [de] Hybridpolypeptide mit auswahlbaren Eigenschaften, [en] Hybrid polypeptides with selectable properties. AMYLIN PHARMACEUTICALS, February 29, 2012: EP2422807-A2

[en] The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabete ...


9
GHOSH SOUMITRA SHANKAR, LEWIS DIANA Y, JANSSEN SAMUEL, SRIVASTAVA VED, LIU QUE, JODKA CAROLYN M, SOARES CHRISTOPHER J, LIN QING: [fr] Composition et procédés pour le traitement de linsuffisance cardiaque congestive, [de] Zusammensetzung und Verfahren zur Behandlung von kongestiver Herzinsuffizienz, [en] Composition and methods for treatment of congestive heart failure. AMYLIN PHARMACEUTICALS, ASTRAZENECA PHARMACEUTICALS, September 11, 2013: EP2636680-A2

[en] Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in ...


10